Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 3/20 | 0.37 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CCR3 | P51677 | 2/20 | 0.35 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | PROKR1 | Q8TCW9 | 5/20 | 0.35 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6302021 | 1.00 | MAPT (0.39) | MAPTTP53KDRFLT1MET | |
| SCHEMBL4709508 | 1.00 | MAPT (0.39) | MAPTTP53KDRFLT1MET | |
| SCHEMBL5837898 | 1.00 | MAPT (0.39) | MAPTTP53KDRFLT1MET | |
| SCHEMBL6753250 | 0.92 | VNN1 (0.38) | MAPTTP53KDRFLT1MET | |
| SCHEMBL5240306 | 0.91 | PDE4A (0.40) | MAPTTP53KDRFLT1MET | |
| SCHEMBL10224379 | 0.87 | MAPT (0.45) | MAPTTP53KDRMETPOLB | |
| SCHEMBL14042997 | 0.85 | TP53 (0.37) | MAPTTP53KDRMETPOLB | |
| SCHEMBL6302397 | 0.85 | TP53 (0.37) | MAPTTP53KDRMETPOLB | |
| SCHEMBL5244194 | 0.85 | TP53 (0.37) | MAPTTP53KDRMETPOLB | |
| SCHEMBL4710650 | 0.85 | TP53 (0.37) | MAPTTP53KDRMETPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6995171-B2 | Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents | AGOURON PHARMACEUTICALS, INC. (US) | 2006-02-07 | — | — | US | disclosed |
| US-20040171590-A1 | Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents | AUTRY CHRISTOPHER (US) | 2004-09-02 | — | — | US | disclosed |
| WO-2003000194-A2 | THIENOPYRIDINE AND THIENOPYRIMIDINE ANTICANCER AGENTS | PFIZER INC. (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171590-A1 | Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents | TK1, TYMP, DPYD | MAPT 4250/4885TP53 11/4885KDR 1886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.